Comment on Herring et al. The Use of "Retardation" in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044

Elspeth Bruford; On Behalf Of The Hugo Gene Nomenclature Committee Hgnc

doi:10.3390/cells11121937

Comment on Herring et al. The Use of "Retardation" in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044

Cells. 2022 Jun 16;11(12):1937. doi: 10.3390/cells11121937.

Authors

Elspeth Bruford^{1

2}, On Behalf Of The Hugo Gene Nomenclature Committee Hgnc²

Affiliations

¹ Department of Haematology, University of Cambridge School of Clinical Medicine, Cambridge CB2 0PT, UK.
² HUGO Gene Nomenclature Committee, EMBL-EBI, European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton CB10 1SD, UK.

Abstract

This commentary is written in response to the recent article from Herring et al., discussing the eradication of the offensive term "retardation" from gene nomenclature. We discuss the work of the HUGO (Human Genome Organisation) Gene Nomenclature Committee (HGNC) and outline the steps already taken to remove this term from our gene names. We also highlight the latest nomenclature changes made as a result of discussions with the authors and agreement with the European Fragile X Network.

Keywords: FMR1; FRAXA; HGNC; fragile X syndrome; gene nomenclature.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Comment

MeSH terms

Fragile X Mental Retardation Protein* / genetics
Fragile X Syndrome* / genetics
Humans

Substances

FMR1 protein, human
Fragile X Mental Retardation Protein

Abstract

Publication types

MeSH terms

Substances

Grants and funding